Last, as demonstrated in vivo, the intravenous injection of cationic BSA (c-BSA) can cause lesions of membranous nephropathy due to the deposition of immune complexes containing anti-BSA IgG and complement component C3 (39–41). Here, C3 is linked to membranous glomerulonephritis.